Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

multiSero: open multiplex-ELISA platform for analyzing antibody responses to SARS-CoV-2 infection

View ORCID ProfileJanie R. Byrum, View ORCID ProfileEric Waltari, Owen Janson, View ORCID ProfileSyuan-Ming Guo, View ORCID ProfileJenny Folkesson, View ORCID ProfileBryant B. Chhun, Joanna Vinden, View ORCID ProfileIvan E. Ivanov, View ORCID ProfileMarcus L. Forst, View ORCID ProfileHongquan Li, View ORCID ProfileAdam G. Larson, View ORCID ProfileWesley Wu, View ORCID ProfileCristina M. Tato, Krista M. McCutcheon, View ORCID ProfileMichael J. Peluso, View ORCID ProfileTimothy J. Henrich, View ORCID ProfileSteven G. Deeks, View ORCID ProfileManu Prakash, View ORCID ProfileBryan Greenhouse, John E. Pak, View ORCID ProfileShalin B. Mehta
doi: https://doi.org/10.1101/2021.05.07.21249238
Janie R. Byrum
1Chan Zuckerberg Biohub, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Janie R. Byrum
Eric Waltari
1Chan Zuckerberg Biohub, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eric Waltari
Owen Janson
2University of California San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Syuan-Ming Guo
1Chan Zuckerberg Biohub, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Syuan-Ming Guo
Jenny Folkesson
1Chan Zuckerberg Biohub, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jenny Folkesson
Bryant B. Chhun
1Chan Zuckerberg Biohub, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bryant B. Chhun
Joanna Vinden
2University of California San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ivan E. Ivanov
1Chan Zuckerberg Biohub, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ivan E. Ivanov
Marcus L. Forst
1Chan Zuckerberg Biohub, San Francisco, CA, USA
3Stanford University, Palo Alto, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marcus L. Forst
Hongquan Li
3Stanford University, Palo Alto, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Hongquan Li
Adam G. Larson
3Stanford University, Palo Alto, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Adam G. Larson
Wesley Wu
1Chan Zuckerberg Biohub, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Wesley Wu
Cristina M. Tato
1Chan Zuckerberg Biohub, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cristina M. Tato
Krista M. McCutcheon
1Chan Zuckerberg Biohub, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Peluso
2University of California San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael J. Peluso
Timothy J. Henrich
2University of California San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Timothy J. Henrich
Steven G. Deeks
2University of California San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Steven G. Deeks
Manu Prakash
1Chan Zuckerberg Biohub, San Francisco, CA, USA
3Stanford University, Palo Alto, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Manu Prakash
Bryan Greenhouse
1Chan Zuckerberg Biohub, San Francisco, CA, USA
2University of California San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bryan Greenhouse
  • For correspondence: bryan.greenhouse{at}ucsf.edu john.pak{at}czbiohub.org shalin.mehta{at}czbiohub.org
John E. Pak
1Chan Zuckerberg Biohub, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: bryan.greenhouse{at}ucsf.edu john.pak{at}czbiohub.org shalin.mehta{at}czbiohub.org
Shalin B. Mehta
1Chan Zuckerberg Biohub, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Shalin B. Mehta
  • For correspondence: bryan.greenhouse{at}ucsf.edu john.pak{at}czbiohub.org shalin.mehta{at}czbiohub.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Serology has provided valuable diagnostic and epidemiological data on antibody responses to SARS-CoV-2 in diverse patient cohorts. Deployment of high content, multiplex serology platforms across the world, including in low and medium income countries, can accelerate longitudinal epidemiological surveys. Here we report multiSero, an open platform to enable multiplex serology with up to 48 antigens in a 96-well format. The platform consists of three components: ELISA-array of printed proteins, a commercial or home-built plate reader, and modular python software for automated analysis (pysero). We validate the platform by comparing antibody titers against the SARS-CoV-2 Spike, receptor binding domain (RBD), and nucleocapsid (N) in 114 sera from COVID-19 positive individuals and 87 pre-pandemic COVID-19 negative sera. We report data with both a commercial plate reader and an inexpensive, open plate reader (nautilus). Receiver operating characteristic (ROC) analysis of classification with single antigens shows that Spike and RBD classify positive and negative sera with the highest sensitivity at a given specificity. The platform distinguished positive sera from negative sera when the reactivity of the sera was equivalent to the binding of 1 ng mL−1 RBD-specific monoclonal antibody. We developed normalization and classification methods to pool antibody responses from multiple antigens and multiple experiments. Our results demonstrate a performant and accessible pipeline for multiplexed ELISA ready for multiple applications, including serosurveillance, identification of viral proteins that elicit antibody responses, differential diagnosis of circulating pathogens, and immune responses to vaccines.

  • multiplex serology
  • automated analysis
  • accessible technology

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04362150

Funding Statement

J.R.B, E.W, S-M.G, J.F, B.B.C, I.E.I, M.L.F, W.W, C.M.T, K.M.M, M.P, B.G, J.E.P, S.B.M are supported by the Chan Zuckerberg Biohub. M.L.F was also supported by the Knight-Hennessy Scholarship and a Graduate Research Fellowship from the National Science Foundation. H.L was supported by Bio-X Stanford Interdisciplinary Graduate Fellowship. This research was supported by the Chan Zuckerberg Biohub and NIH/NIAID 3R01AI141003-03S1 (to TJ Henrich).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

COVID-19 positive sera were collected during the LIINC study(https://www.liincstudy.org, NCT04362150), which was approved by the UCSF Institutional Review Board (IRB). The negative pool used in Fig.3A-B was made of sera collected under a study approved by UCSF IRB (10-03852). All subjects provided written informed consent. Authors received de-identified pre-pandemic COVID-19 negative sera from the New York Blood Center (NYBC). These samples were collected from volunteer blood donors, who consented to the use of donated blood for transfusion and research.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The images of SARS-CoV-2 ELISA-array assayed with 189 sera, spread over 6 plates, are available publicly via google drive (https://bit.ly/34ZjdtQ). The python code to analyze this data is available from this GitHub repository (https://github.com/czbiohub/pysero). The repository also includes code and instructions to reproduce fig. 4 from above images.

https://bit.ly/34ZjdtQ

https://github.com/czbiohub/pysero

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted May 11, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
multiSero: open multiplex-ELISA platform for analyzing antibody responses to SARS-CoV-2 infection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
multiSero: open multiplex-ELISA platform for analyzing antibody responses to SARS-CoV-2 infection
Janie R. Byrum, Eric Waltari, Owen Janson, Syuan-Ming Guo, Jenny Folkesson, Bryant B. Chhun, Joanna Vinden, Ivan E. Ivanov, Marcus L. Forst, Hongquan Li, Adam G. Larson, Wesley Wu, Cristina M. Tato, Krista M. McCutcheon, Michael J. Peluso, Timothy J. Henrich, Steven G. Deeks, Manu Prakash, Bryan Greenhouse, John E. Pak, Shalin B. Mehta
medRxiv 2021.05.07.21249238; doi: https://doi.org/10.1101/2021.05.07.21249238
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
multiSero: open multiplex-ELISA platform for analyzing antibody responses to SARS-CoV-2 infection
Janie R. Byrum, Eric Waltari, Owen Janson, Syuan-Ming Guo, Jenny Folkesson, Bryant B. Chhun, Joanna Vinden, Ivan E. Ivanov, Marcus L. Forst, Hongquan Li, Adam G. Larson, Wesley Wu, Cristina M. Tato, Krista M. McCutcheon, Michael J. Peluso, Timothy J. Henrich, Steven G. Deeks, Manu Prakash, Bryan Greenhouse, John E. Pak, Shalin B. Mehta
medRxiv 2021.05.07.21249238; doi: https://doi.org/10.1101/2021.05.07.21249238

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)